Overview
Adecatumumab (MT201)
Blinatumomab (MT103)
MT110
MT203
MT293 (TRC093)
Preclinical Candidates
 
About UsPipelineTechnologyPartneringInvestor RelationsCareers
 
   
 
BiTE® Antibody Pipeline Overview
Product Development Stage Indication Target Marketing Rights
Blinatumomab (MT103) Phase 1, Phase 2 Non-Hodgkin´s Lymphoma, Acute Lymphocytic Leukemia CD19 Micromet
MT110 Phase 1 Solid Tumors EpCAM Micromet
MT111 Preclinical Solid Tumors CEA Micromet (EU)
MedImmune#1 (ROW)
BiTE antibody Preclinical Solid Tumors not disclosed Bayer Schering
BiTE N.N. Research Solid Tumors not disclosed sanofi-aventis
MCSP BiTE Antibody Research, Lead Optimization Melanoma MCSP Micromet
EGFR BiTE Antibody Research, Lead Optimization Adenocarcinoma EGFR Micromet
CD33 BiTE Antibody Research, Lead Optimization Myelogenous Leukemia CD33 Micromet
#1 MedImmune is a wholly owned subsidiary of AstraZeneca PLC
Back
 
   
ContactDirectionsEmail Alert 
HomeImprintLegal Notices